Search Login Register
TNFR-Fc fusion protein
(etanercept)
Summary
Description:
reduces tumor necrosis factor activity, as well as cytokine, chemokine, and stress hormone release; used to treat SPONDYLITIS, ANKYLOSING
Also Known As:
etanercept; Enbrel; Immunex brand of etanercept; TNF receptor type II-IgG fusion protein; TNR 001 Show All >>
Networked: 3122
relevant articles (575 outcomes,
664 trials/studies)
for this Drug
Key Diseases for which TNFR-Fc fusion protein is
Relevant
-
Psoriasis (Pustulosis Palmaris et Plantaris)
:
156 outcomes 173 studies in 715 results
-
Rheumatoid Arthritis
:
126 outcomes 152 studies in 901 results
-
Ankylosing Spondylitis
:
51 outcomes 59 studies in 246 results
-
Psoriatic Arthritis
:
45 outcomes 57 studies in 297 results
-
Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
:
43 outcomes 26 studies in 195 results
Show All >>
Drugs Related to TNFR-Fc fusion protein
-
infliximab (Remicade)
-
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
-
adalimumab (Humira)
-
Methotrexate (Mexate)
-
TNFR-Fc fusion protein (etanercept)
-
Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
-
monoclonal antibody CNTO 1275 (CNTO 1275)
-
Antirheumatic Agents (DMARD)
-
efalizumab
-
golimumab
Show All >>
Therapies Related to TNFR-Fc fusion protein
-
Phototherapy (Light Therapy)
-
Aftercare (After-Treatment)
-
Biological Therapy
-
Remission Induction
-
Laminectomy
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.